PT-141: the best-evidenced compound here, and still the wrong evidence for most of its users

The short version

PT-141, approved under the name bremelanotide, is a small ring-shaped peptide that acts on the brain rather than on blood vessels. Drugs like sildenafil work on the plumbing; this one works on the wiring, switching on melanocortin receptors in the hypothalamus that sit upstream of sexual desire ^[22].

By the standards of this desk it is the best-evidenced compound here. It carries an FDA approval granted in 2019, two identical Phase 3 randomised trials with 1,267 participants between them ^[20], and a 52-week open-label extension in 684 women ^[21]. Compared with the two-person pilot behind BPC-157, that is a different universe of evidence.

The gaps are elsewhere, and there are three. The approval covers one group only: premenopausal women with acquired, generalised low sexual desire. Use in men, in postmenopausal women, or for performance is off-label and untrialled at that level, which means the largest community discussing the compound is outside the studied population entirely. The effect sizes that earned the approval were statistically clear and numerically small ^[20], and whether they are large enough to notice has been publicly contested. And the mechanism is genuinely unsettled: a 2025 animal study and a 2022 human imaging study point at different circuits ^[18][19].

What it is

PT-141 is a synthetic cyclic heptapeptide, meaning a ring of seven amino acids, built as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is written Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge tying the Asp and Lys side chains into the ring. It is structurally related to melanotan II, with the C-terminal amide replaced by a carboxylic acid, which is the change that shifts its profile toward sexual function and away from tanning.

It was approved by the FDA in June 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women. The label specifies a 1.75 mg subcutaneous amount taken as needed, no more than one in 24 hours and no more than eight in a month; a terminal half-life of about 2.7 hours with a range of 1.9 to 4.0; a volume of distribution of 25.0 litres; clearance of 6.5 litres per hour; and excretion of 64.8 percent renally and 22.8 percent in faeces. It carries a warning about a transient rise in blood pressure and is contraindicated in uncontrolled hypertension or known cardiovascular disease ^[22].

Material sold as PT-141 research chemical is a separate thing from the approved product. It sits outside the pharmaceutical approval framework, with no regulatory oversight of identity, purity or concentration, and nothing about the approval transfers to it.

How it works, and why that is still an open question

The plain-language version: most treatments for sexual difficulty act on blood flow. This one acts on interest. It turns on melanocortin receptors, chiefly MC4R and to a lesser extent MC3R, that are concentrated in the hypothalamus and the limbic system, and from there it is thought to engage the dopamine pathways that govern sexual motivation. Whatever else is unclear, the fact that it works centrally rather than peripherally is well supported and is what distinguishes it from the PDE-5 inhibitors ^[22].

Beyond that, the story gets genuinely contested, and this is the most interesting gap on the page because it is not a gap of missing data but of data that disagree.

A 2022 human study did the direct thing: 31 premenopausal women with low desire took part in a randomised, double-blind, placebo-controlled crossover trial with functional MRI. MC4R agonism significantly increased sexual desire for up to 24 hours, and it altered how the brain processed erotic material, with enhanced functional connectivity between the amygdala and the insula and changed cerebellar and supplementary-motor activity ^[19].

A 2025 study in female Syrian hamsters looked at the reward circuit instead and returned a negative result. Melanocortin receptor messenger RNA was concentrated in dopamine neurons of the ventral tegmental area, but neither the low nor the high amount of bremelanotide changed melanocortin-receptor expression in the mesolimbic dopamine system, and the compound did not enhance sexual reward as measured by conditioned place preference. The authors read that as evidence it does not act through the ventral tegmental area to nucleus accumbens reward pathway ^[18].

Two models, two circuits, no reconciliation. That is not a scandal; it is normal science in progress. It does mean that any confident sentence about how PT-141 produces desire is running ahead of the literature.

What the research shows, and what each study leaves open

The Phase 3 programme, 2019. Two identical randomised, double-blind, placebo-controlled trials, together known as RECONNECT, enrolled 1,267 premenopausal women with hypoactive sexual desire disorder. Over 24 weeks, the 1.75 mg subcutaneous as-needed regimen produced a statistically significant improvement in the desire domain of the Female Sexual Function Index, an integrated change of +0.35, and a significant reduction in desire-related distress, an integrated change of -0.33 on the relevant item, both at P below .001. The most common adverse events were nausea, flushing and headache ^[20]. Left open: the coprimary endpoints were met and the effect sizes are small numbers on their scales. Critical re-analyses have argued publicly that the effects, while statistically significant, are of questionable clinical meaningfulness, and have raised concerns about the outcome measures themselves. No trial in this programme independently anchored how much change on those scales a person actually notices, which is the question the dispute turns on.

The 52-week extension, 2019. 684 women continued in an open-label extension. No new safety signals emerged and the improvement in desire was sustained. The most common drug-related treatment-emergent adverse events were nausea at 40.4 percent, flushing at 20.6 percent and headache at 12.0 percent ^[21]. Left open: two things. The extension is open-label, so beyond 24 weeks there is no placebo comparison, and sustained improvement in an unblinded study is a weaker claim than it sounds. And 52 weeks is the ceiling of the published safety record, which matters most for the effects that accumulate with exposure rather than appearing at once.

Human brain imaging, 2022. The crossover fMRI study in 31 women described above, showing increased desire for up to 24 hours and altered amygdala-insula connectivity ^[19]. Left open: 31 participants, a single administration, and an imaging endpoint. It shows the brain does something different; it does not show which change produces the effect.

Animal reward-circuit study, 2025. The female Syrian hamster work described above, which found no enhancement of sexual reward and no change in melanocortin-receptor expression in the mesolimbic dopamine system ^[18]. Left open: it is a hamster, and a negative result in one model does not close a mechanism. It does, however, sit awkwardly against the confident dopamine-reward story that circulates informally.

The prescribing information, 2019. The authoritative source for the approved indication, the regimen, the pharmacokinetics and the contraindications, as set out above ^[22]. Left open: every number in it was established in premenopausal women. There is no published pharmacokinetic profile for the population that uses the compound off-label, so even the half-life of about 2.7 hours is a figure borrowed from a different group ^[22].

One further item belongs on a gap register. A 2023 Expression of Concern was issued for a 2008 erectile-dysfunction salvage study by Safarinejad and Hosseini, which means part of the older male-use evidence base is formally disputed rather than merely thin.

Reported effects, cautions and safety

What follows in this first part is anecdotal, not clinical evidence. It is drawn from research-use forums and consumer review sites, describes people using both approved and unregulated material, and carries no verified product identity and no amounts.

The effect reported most often is a felt increase in sexual desire that people describe as starting in the head rather than the body, a sense of wanting rather than of physical response. Greater physical arousal and sensitivity is frequently reported, sometimes building without direct stimulation. Easier or more intense orgasm is frequently reported as a secondary effect. In the off-label male community, spontaneous erections are frequently reported and described as feeling different from blood-flow drugs because the urge arrives first. A stronger sense of emotional closeness is occasionally reported. A slow onset and a long window, commonly described as half an hour to a few hours before effects appear and lasting well into the next part of the day, is frequently reported and viewed by some as an advantage and by others as a planning problem. Non-response is a real and recurring report: some people describe getting the side effects and none of the benefit.

On the unwanted side, nausea is by far the most commonly reported complaint and the one most likely to make people stop, usually starting within about half an hour, lasting a couple of hours and easing with later use. Flushing and warmth is frequently reported, as are headache and injection-site irritation. Tingling or pins-and-needles, heightened skin sensitivity, brief anxiety, and fatigue or drowsiness are occasionally reported. With repeated frequent use, some people report darkening of skin, gums, freckles or existing moles, and some report that the darkening did not fully fade after stopping.

The documented cautions are these.

• Approved for one population; everything else is off-label. The approval covers acquired, generalised low sexual desire in premenopausal women. Use in men, in postmenopausal women, or to enhance performance has not been approved and was not what the Phase 3 programme studied ^[20][22].
• Transient blood-pressure rise. The compound causes a short-lived increase in blood pressure after use, with a matching small drop in heart rate, before returning to baseline. The label warns against use in uncontrolled hypertension or known cardiovascular disease ^[22].
• Nausea is common enough to limit use. It affected 40.4 percent of participants over 52 weeks of open-label use and is a leading reason people discontinue ^[20][21].
• Skin and mucous-membrane darkening with frequent use. Because the compound also activates pigment-related receptors, repeated frequent use can darken the face, gums and breasts and change moles or freckles, more likely in people with darker baseline skin, and it may not fully reverse. The labelled limit on how often it is used exists partly to reduce this ^[22].
• A liver signal is recorded outside this site's source list. The NIH LiverTox monograph notes mild rises in liver-related blood markers and, rarely, clinically apparent liver injury. That monograph is not among the references listed here, so it is flagged rather than summarised.
• Research-chemical supply has no quality control. Material sold under the PT-141 name sits outside the approval framework, with identity, purity and concentration unverified.
• Appetite effects are an off-target consideration, not a use. MC4R also helps regulate appetite, so effects on food intake and body weight are a pharmacological consequence of the same receptor and not an approved application.
• Pregnancy and breastfeeding are unstudied, and no controlled human data establish safety in those situations.

Where it fits in the gap register

PT-141 is the population case, and it is the most instructive entry here precisely because its evidence is good. An approval, two Phase 3 trials, 1,267 participants and a year of follow-up ^[20][21] is not a thin record by any standard. The gap is that the record answers a question about one group of people while most of the conversation about the compound concerns other groups.

That is a different failure from the one on the BPC-157 page. BPC-157's problem is that the human studies do not exist. PT-141's problem is that they exist and were conducted somewhere else, in a different population, at a defined regimen, over a defined period. Evidence does not travel between populations for free, and the further a use sits from the studied group, the more of the approval's authority it loses.

The second gap is quieter and matters more than it looks. A 52-week ceiling on published safety data ^[21] is a poor fit for an effect like progressive pigment change, which builds with cumulative exposure and would be systematically under-detected in a one-year open-label window. The safety record is not wrong; it is simply shorter than one of the risks it is asked to cover.

And the third is the mechanism disagreement between the human imaging and the animal reward work ^[18][19]. On a desk that catalogues absences, a live contradiction is worth more than a confident summary. See the comparison page for how all four fit together.